论文部分内容阅读
目的评价依达拉奉、巴曲酶和阿司匹林联合治疗急性脑梗死的疗效及安全性。方法对2004年4月￣2006年1月广东省普宁华侨医院80例急性脑梗死住院患者,随机分为治疗组和对照组各40例。治疗组应用依达拉奉、巴曲酶和阿司匹林联合治疗;对照组应用巴曲酶和阿司匹林治疗;评价两组治疗前及治疗后3d、7d、14d、28d、90d的神经功能缺损评分和90d后疗效。结果治疗组基本痊愈率及有效率高于对照组(P<0.05),且起效快,不增加不良反应。结论依达拉奉、巴曲酶和阿司匹林联合治疗急性脑梗死比巴曲酶和阿司匹林治疗效果更好,且较安全。
Objective To evaluate the efficacy and safety of edaravone, batroxobin and aspirin in the treatment of acute cerebral infarction. Methods From April 2004 to January 2006, 80 cases of acute cerebral infarction hospitalized in Puning Overseas Chinese Hospital of Guangdong Province were randomly divided into treatment group (40 cases) and control group (40 cases). The treatment group was treated with edaravone, batroxobin and aspirin. The control group was treated with batroxobin and aspirin. The neurological deficit scores of the two groups were evaluated before and after treatment for 3d, 7d, 14d, 28d, 90d and 90d After the effect. Results The cure rate and the effective rate of the treatment group were higher than those of the control group (P <0.05), and the onset rate was fast without increasing the adverse reactions. Conclusion The combination of edaravone, batroxobin and aspirin is better than batroxobin and aspirin in the treatment of acute cerebral infarction.